Paliperidone (Invega) manufacturer withdraws application for its use in bipolar disorder
Reproduction of EMEA’s press release about the Janssen-Cilag International application withdrawal for an extension of indication for Invega (paliperidone): PRESS RELEASE Janssen-Cilag International N.V. withdraws its application for an extension of indication for Invega (paliperidone) The European Medicines Agency (EMEA) has been formally notified by Janssen-Cilag International N.V. of its decision to withdraw its application […]
Antipsychotics for acute and chronic pain: a systematic review
Summary Analgesic effects of antipsychotics in acute and chronic painful states Antipsychotics are used in different chronic pain states (e.g. chronic headache, fibromyalgia and diabetic neuropathia). With atypical antipsychotics a new class of antipsychotics is available, with lesser extrapyramidal side effects and additional benefits. The review authors assessed the analgesic efficacy and adverse effects of […]
Risk of death in patients with dementia that use typical antipsychotics: EMEA’s press release
Questions and answers on the review of the use of conventional antipsychotic medicines in elderly patients with dementia The European Medicines Agency (EMEA) has completed a review of the evidence available on the safety of conventional antipsychotic medicines in elderly patients with dementia. The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that there […]
SSRIs, SNRIs and SSNRIs: clinical guideline by the ACP
The American College of Physicians has issued a Clinical Practice Guideline about the use of Second-Generation Antidepressants in the treatment of Depressive Disorders. The recommendations that arise from it are the following: Recommendation 1: The American College of Physicians recommends that when clinicians choose pharmacologic therapy to treat patients with acute major depression, they select […]